Van Cleef Asset Management Inc Sells 1,426 Shares of Pfizer Inc. (NYSE:PFE)

Van Cleef Asset Management Inc cut its position in Pfizer Inc. (NYSE:PFE) by 1.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,569 shares of the biopharmaceutical company’s stock after selling 1,426 shares during the quarter. Pfizer comprises approximately 1.0% of Van Cleef Asset Management Inc’s holdings, making the stock its 27th biggest position. Van Cleef Asset Management Inc’s holdings in Pfizer were worth $4,573,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Heritage Way Advisors LLC grew its stake in shares of Pfizer by 0.6% in the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock valued at $2,492,000 after buying an additional 354 shares in the last quarter. Natixis bought a new position in shares of Pfizer in the second quarter valued at $258,466,000. Machina Capital S.A.S. boosted its position in Pfizer by 14.4% during the second quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock worth $1,899,000 after purchasing an additional 5,522 shares during the period. M Holdings Securities Inc. boosted its position in Pfizer by 27.9% during the first quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock worth $1,692,000 after purchasing an additional 8,693 shares during the period. Finally, Annex Advisory Services LLC boosted its position in Pfizer by 0.7% during the second quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock worth $2,243,000 after purchasing an additional 382 shares during the period. 71.84% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, July 29th. Bank of America cut shares of Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective for the company in a research report on Wednesday, August 28th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $49.00 price objective on shares of Pfizer in a research report on Monday, June 17th. Fifteen analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus price target of $45.88.



In related news, Director Scott Gottlieb purchased 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was acquired at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at $104,160. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Frank A. Damelio sold 153,184 shares of the business’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the completion of the transaction, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

PFE stock traded down $0.50 during midday trading on Friday, reaching $36.78. The company had a trading volume of 931,532 shares, compared to its average volume of 21,779,912. The company has a market capitalization of $207.47 billion, a price-to-earnings ratio of 12.27, a price-to-earnings-growth ratio of 2.97 and a beta of 0.65. The stock has a 50 day moving average price of $36.81 and a 200-day moving average price of $40.81. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $46.47. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. The business had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. Pfizer’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.77 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 2.81 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd were paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 3.92%. The ex-dividend date was Thursday, August 1st. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Convertible Shares

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.